PharmaDrug to Present at Wall Street Reporter’s “Next Super Stock” Live Conference on Tuesday, January 25, 2022


Toronto, Ontario–(Newsfile Corp. – January 24, 2022) – PharmaDrug Inc. (CSE: PHRX) (OTCQB: LMLLF) (FSE: G111) (“PharmaDrug“or the”Society“), a specialty pharmaceutical company focused on the development and commercialization of controlled substances and natural medicines such as psychedelics, cannabis and approved medicines of natural origin, is pleased to announce that the President and Chief Executive Officer of the company, Daniel Cohen, will present the reporter’s “Next Super Stock” Live Wall Street Conference on January 25, 2022.


Daniel Cohen, Chairman and CEO of PharmaDrug, will update investors on the company’s latest plans, developments and targets for its biotechnology initiatives, including its research and development programs for cepharantine and DMT.

PharmaDrug’s live presentation will take place at 1:00 p.m. Eastern Time on January 25, 2022.

The 20-minute presentation will be followed by a question-and-answer session. To learn more about the event and register for free: CLICK HERE TO REGISTER

For those unable to attend the live event, a video of the presentation will be posted later.

About the “Next Super Stock” conference:

“NEXT SUPER STOCK Live!” from Wall Street Reporter The conference is dedicated to showcasing select companies that have in place near-term catalysts that can drive transformational growth (and stock appreciation) in the months ahead.

About PharmaDrug Inc.

PharmaDrug is a specialty pharmaceutical company focused on the research, development and commercialization of controlled substances and natural medicines such as psychedelics, cannabis and approved medicines of natural origin. PharmaDrug owns 100% of Pharmadrug Production GmbH (“Pharmadrug Production”), a German distributor of medical cannabis, with a European Union Schedule I narcotics license and German EuGMP certification allowing the import and distribution of medical cannabis to pharmacies in Germany and throughout Europe. Union. PharmaDrug owns 100% of Sairiyo Therapeutics (“Sairiyo”), a biotechnology company specializing in the research and reformulation of established natural medicines with the goal of bringing them through clinical trials and the associated regulatory approval process in the United States. United and Europe. Sairiyo is currently developing its patented reformulation of cepharanthine, a drug that has shown substantial third-party validated potential for the treatment of Covid-19 and rare cancers. Sairiyo also conducts R&D activities in the field of psychedelics for the treatment of non-neuropsychiatric diseases. The company also owns 100% of Super Smart, a company that is building a vertically integrated retail business with the goal of increasing the use of functional mushrooms and psilocybin mushrooms, where federally legal, as than natural medicines.

For more information, please contact:

Daniel Cohen, President and CEO
(647) 202-1824

Caution Regarding Forward-Looking Information:


This press release contains “forward-looking information” within the meaning of applicable securities laws. All statements, other than statements of historical fact, included herein are forward-looking information. Generally, forward-looking information can be identified by the use of forward-looking terminology such as “anticipates”, “anticipates” or “does not expect”, “proposed”, “is planned”, “budgets”, ” intended”, “estimates”, “plans”, “intends”, “anticipates” or “does not anticipate”, or “believes”, or variations of these words and expressions, or by the use of words or phrases indicating that certain actions, events or results can, might, might occur or be achieved. In particular, this press release contains forward-looking information regarding: the development and commercialization of cepharanthine, the results of the Company’s research and development in the field of psychedelics and the development of the Supersmart business. This forward-looking information reflects the Company’s current beliefs and is based on information currently available to the Company and on assumptions the Company believes are reasonable. These assumptions include, but are not limited to, the Company’s ability to successfully execute its plans for the Company and its affiliated entities; the ability to obtain required regulatory approvals and the Company’s continued response and ability to navigate the COVID-19 pandemic is at or better than its ability and response to date.

Forward-looking information is subject to known and unknown risks, uncertainties and other factors that may cause the actual results, level of activity, performance or achievements of the Company to be materially different from those expressed or implied. by such forward-looking information. These risks and other factors may include, but are not limited to: general business, economic, competitive, political and social uncertainties; general capital market conditions and securities market prices; the actual results of future operations of the Company; competetion; changes in legislation affecting the Company; the ability to obtain and maintain required permits and approvals, the timing and availability of external financing on acceptable terms; lack of skilled and skilled labor or loss of key individuals; risks related to the COVID-19 pandemic, including various recommendations, orders and measures by government authorities in an attempt to limit the pandemic, including travel restrictions, border closures, closures of non-essential businesses, service disruptions, quarantines, self-isolation, shelter-in-geographic and social distancing, disruptions in markets, economic activity, financing, supply chains and sales channels, and a deterioration in general economic conditions; and a deterioration in the financial markets which could limit the Company’s ability to obtain external financing.

A description of additional risk factors that could cause actual results to differ materially from the forward-looking information can be found in the Company’s disclosure documents on the SEDAR website at Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in the forward-looking information, there may be other factors that cause results not to be those anticipated, estimated or expected. Readers are cautioned that the above list of factors is not exhaustive. Readers are further cautioned not to place undue reliance on forward-looking information, as there can be no assurance that the plans, intentions or expectations upon which it is based will occur. Such information, although considered reasonable by management when prepared, may prove to be incorrect and actual results may differ materially from those anticipated.

The Company’s securities have not been registered under the US Securities Act of 1933, as amended (the “US Securities Act”), or applicable state securities laws, and may not be offered or sold to , or for the account or benefit of, persons in the United States or “US Persons”, as that term is defined in the Regulations under the US Securities Act, in the absence of registration or an applicable exemption these registration requirements. This press release does not constitute an offer to sell or the solicitation of an offer to buy and there will be no sale of the securities in the United States or in any jurisdiction in which such offer, solicitation or sale would be unlawful. .

The forward-looking information contained in this press release is expressly qualified by this cautionary statement. The forward-looking information contained in this press release represents the Company’s expectations as of the date of this press release and, accordingly, is subject to change after such date. However, the Company expressly disclaims any intention or obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as expressly required by securities laws. applicable securities.

To view the source version of this press release, please visit


Comments are closed.